P

Piramal Pharma Ltd
NSE:PPLPHARMA

Watchlist Manager
Piramal Pharma Ltd
NSE:PPLPHARMA
Watchlist
Price: 219.83 INR 5.5% Market Closed
Market Cap: 290.3B INR

Piramal Pharma Ltd
Other Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Piramal Pharma Ltd
Other Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
P
Piramal Pharma Ltd
NSE:PPLPHARMA
Other Liabilities
â‚ą2B
CAGR 3-Years
212%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Other Liabilities
â‚ą5.5B
CAGR 3-Years
30%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Other Liabilities
â‚ą3.3B
CAGR 3-Years
6%
CAGR 5-Years
-7%
CAGR 10-Years
10%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Other Liabilities
â‚ą9.2B
CAGR 3-Years
-5%
CAGR 5-Years
-6%
CAGR 10-Years
-10%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Other Liabilities
â‚ą4.7B
CAGR 3-Years
6%
CAGR 5-Years
7%
CAGR 10-Years
9%
M
Mankind Pharma Ltd
NSE:MANKIND
Other Liabilities
â‚ą1.5B
CAGR 3-Years
22%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

Piramal Pharma Ltd
Glance View

Market Cap
290.1B INR
Industry
Pharmaceuticals

Piramal Pharma Ltd. has embarked on a remarkable journey that reflects the dynamic world of pharmaceuticals and healthcare. Emerging from the rich tapestry of the Piramal Group's diverse business ventures, it has carved out a distinctive place for itself in the global pharmaceutical landscape. The company primarily navigates through three major streams: Contract Development and Manufacturing Organization (CDMO), Critical Care, and Consumer Products. Its CDMO division is the backbone, providing end-to-end solutions spanning the entire drug lifecycle, from development through to commercial manufacturing. By offering tailored solutions to pharmaceutical companies globally, Piramal Pharma not only strengthens its revenue streams but also builds lasting partnerships with some of the world’s leading pharmaceutical innovators. Beyond the realm of CDMO, Piramal Pharma's Critical Care segment specializes in catering to the acute care sector, dealing especially with inhalation anesthesia and pain management solutions. This division operates globally, emphasizing a diligent supply chain that ensures these life-sustaining products reach hospitals and clinics around the world. Meanwhile, its Consumer Products business makes a concerted effort to touch lives in a different manner—through over-the-counter health solutions that meet everyday health concerns of countless individuals. Operating at this unique intersection where science meets humanity, Piramal Pharma not only thrives through product sales but also invests heavily in R&D, seeking out innovative ways to address evolving market needs and inch its way forward in the competitive pharmaceutical arena.

PPLPHARMA Intrinsic Value
147.12 INR
Overvaluation 33%
Intrinsic Value
Price
P

See Also

What is Piramal Pharma Ltd's Other Liabilities?
Other Liabilities
2B INR

Based on the financial report for Mar 31, 2024, Piramal Pharma Ltd's Other Liabilities amounts to 2B INR.

What is Piramal Pharma Ltd's Other Liabilities growth rate?
Other Liabilities CAGR 3Y
212%

Over the last year, the Other Liabilities growth was -1%. The average annual Other Liabilities growth rates for Piramal Pharma Ltd have been 212% over the past three years .

Back to Top